Alkermes plc (ALKS) is listed on NASDAQ in Pharmaceutical Stocks. It is $47.41, -3.05%, with a $8.0B market cap. RSI is 37.2, near oversold. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 37.2 Near Oversold
Market Cap $8.0B
Volume 894.5K
Fundamentals — 10-Q Q2 2026
Revenue $888.9M
Net Income $-66.0M
EPS $-0.40
Gross Margin 82.0%
Operating Margin -3.4%
Net Margin -7.4%
Debt / Equity 0.8x
P/E Ratio -118.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Nichols Christian Todd | SVP, Chief Commercial Officer | Sell | 7,576 | $49.23 | $372,937 | 2026 Aug 17 |
| Snyderman Nancy Lynn Md | Director | Sell | 44,472 | $50.35 | $2.2M | 2026 Aug 3 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $48.58 | $437,220 | 2026 Aug 3 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $48.58 | $98,812 | 2026 Aug 3 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $54.03 | $109,897 | 2026 Jul 6 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $51.51 | $463,621 | 2026 Jul 1 |
| Wright Christopher I | Director | Sell | 2,000 | $45.10 | $90,200 | 2026 Jun 12 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $43.05 | $87,564 | 2026 Jun 4 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $41.67 | $375,044 | 2026 Jun 1 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 16,217 | $42.36 | $687,007 | 2026 May 29 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $33.20 | $67,529 | 2026 May 4 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $33.40 | $300,560 | 2026 May 1 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2,034 | $34.57 | $70,315 | 2026 Apr 6 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $35.51 | $319,604 | 2026 Apr 1 |
| Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 4,068 | $29.53 | $120,108 | 2026 Mar 3 |
| Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 6,890 | $29.29 | $201,808 | 2026 Mar 2 |
| Nichols Christian Todd | SVP, Chief Commercial Officer | Sell | 6,000 | $30.00 | $180,000 | 2026 Mar 2 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9,000 | $29.72 | $267,485 | 2026 Mar 2 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 3,748 | $30.00 | $112,440 | 2025 Dec 3 |
| Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 4,000 | $29.30 | $117,200 | 2025 Dec 1 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $61.02 | 60.3 | $10.1B |
| | $44.82 | 51.9 | -- |
| | $24.11 | 48.8 | $12.0B |
| | $90.36 | 35.0 | $8.0B |
| | $34.17 | 49.9 | $2.5B |
Take ALKS further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put ALKS in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Alkermes plc next reports.
Set alerts on ALKS
Get notified when Alkermes plc hits your price targets or technical conditions are met.
Get Started Free